Heart Century — Coronary Heart Disease AI Accurate Diagnostic Expert
Accurate observation of'heart',Help protect the 'heart'

With a number of core technologies and patented technologies in the field of medical imaging

the cardiovascular imaging intelligent analysis platform is built based on artificial intelligence, cloud computing and big data.

At present, our company is cooperating with Fuwai and many top three hospitals to do clinical trialsIt is expected to become the first approved enterprise in this field in China

Functional evaluation of coronary artery stenosis: CT-FFR

which means that it is possible to obtain coronary FFR values in a non-invasive, low-cost, and efficient manner.

Core Product

Functional Evaluation of Coronary Artery Stenosis — CT-FFR

  • Non-invasive

  • low-cost

  • efficient

CT-FFR

Our company independently developed the CT-FFR, a functional evaluation program for coronary artery stenosis, which effectively solved the non-invasive measurement problem of FFR and was inexpensive. Using artificial intelligence to analyze coronary CT data, simulation calculations to obtain FFR values, to provide a basis for decision-making for subsequent treatment options.

Learn more

Expert Reviews

  • Foreign evaluation of non-invasive FFR
  • Domestic evaluation of non-invasive FFR
James Min(Director, Cardiovascular Imaging Center, Cornell Medical College)

The use of non-invasive FFR has been shown to have a better diagnostic value for all patients and all blood vessels than CT alone.

Raymond Dalio( the godfather of the hedge fund)

After learning about non-invasive FFR technology in 2013, he donated $20 million to Cornell Medical College to establish a cardiovascular imaging center.

William Maisel(Chief Scientist, FDA Equipment and Radiological Health Center)

"This non-invasive diagnostic technology provides a new tool for physicians who are considering the risks and benefits of coronary surgery."

Zhou Yujie(Deputy Dean of Anzhen Hospital)

Compared with FFR, FFFCT determined that the accuracy, specificity, positive and negative predictive value of myocardial ischemic lesions have a good correlation with FFR, and highly suggest that noninvasive evaluation is an inevitable trend in the development of cardiology, and also indicates coronary artery. The evaluation and treatment of lesions will be fully advanced to a new era of combination of morphology and function. At present, Anzhen Hospital has also carried out research on virtual coronary intervention, in order to optimize the choice of patients for invasive treatment, and to plan the entire treatment strategy through this technology.

Lu Bin(Director, Department of Radiology, Fuwai Hospital)

Because FFRCT has a wide range of clinical applications, it is non-invasive. On the basis of a coronary anatomical assessment completed in one scan, the functional parameters of the lesion can be obtained without rescanning. I believe that it must have broad application prospects.

Xu Yawei(Director, Department of Cardiology,The Tenth People's Hospital affiliated to Tongji University)

"FFR-CT, a new technology, brings new hope to the early diagnosis of coronary heart disease, and it will have broad application prospects."

About US

Beijing Heart Century Medical Technology Co., Ltd. was established in 2017. The company is committed to using artificial intelligence technology to transform the medical industry and contribute to life and health. The company currently has a number of core technologies and patented technologies in the field of medical imaging. Based on artificial intelligence, cloud computing and big data, the company has built a cardiovascular imaging intelligent analysis platform to provide better detection and treatment services for heart disease patients. The core team consists of Tsinghua University and overseas students, as well as artificial intelligence experts and medical experts with many years of experience in medical imaging. The core technology of the product has been completed and verified at home and abroad, reaching the international leading level.

Cooperative organization

At present, our company is cooperating with Fuwai and many top three hospitals to do clinical trials.It is expected to become the first approved enterprise in this field in China.
  • 阜外医院
  • 朝阳医院
  • 清华工研院
  • 齐鲁医院
  • 邵逸夫医院
Leave Us a Message

  • Add:Block D 310, Building 2, Dongsheng International Science Park, 1 Yongtaizhuang North Road, Haidian District, Beijing
  • Contact:info@heartcentury.com
  • Apply:hr@heartcentury.com

Heart Century WeChat Public

© 2019 北京心世纪医疗科技有限公司 版权所有 京ICP备14045321-1号 京ICP备14045321-1号 Technical Support:YCXF